Chippaux Jean-Philippe auteur aut IRD Goyffon M. auteur aut IRD text journalArticle eng text/pdf born digital access A century after the discovery of antivenom and despite real progress undertaken in its manufacture, its use remains largely empirical. Recent studies of pharmacokinetics of envenoming permitted improved understanding of immunotherapy. Improved purification of the antivenom by using immunoglobulin fragments has lead to increased tolerance and efficiency of antivenom. The respective advantages and disadvantages of F(ab')2 and F(ab) are discussed in relation to neutralising efficacy and clearance from the circulation. Although the time during which the action of antivenom remains beneficial after the bite is unknown, the superiority of intravenous administration has now been proved. Although immunisation procedures and purification and use of IgG fragments can be improved using modern technology, the future of immunotherapy seems promising. It is vital that therapeutic protocols should be rigidly adhered to in order to optimise immunotherapy. The use of vaccination has yet to be explored. specialized SERPENT TOXICITE TRAITEMENT MEDICAL HISTOIRE PREPARATION MEDICINALE VACCINATION IMMUNOTHERAPIE SERUM ANTIVENIMEUX MORSURE VENIN 050MEDECI 36 6 823-846 1998 0041-0101 https://www.documentation.ird.fr/hor/fdi:010027837 10.1016/S0041-0101(97)00160-8 0041-0101 [F B010027837] https://www.documentation.ird.fr/hor/fdi:010027837 https://www.documentation.ird.fr/intranet/publi/2024-06/010027837.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2002-01-17 2024-06-20 fdi:010027837 fre